TFF Pharmaceuticals (TFFP)
(Delayed Data from NSDQ)
$1.81 USD
-0.14 (-7.18%)
Updated May 13, 2024 03:59 PM ET
After-Market: $1.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 41 - 60 ( 148 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TFF VORI and TFF TAC on Track For Interim Data in 2H22; Reiterate Buy Rating and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Many Collaborations- Something''s Got to Give Bringing Non-Dilutive $
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
When it Comes to TFF in the Lung, Nothing But Drug; Assuming Coverage at Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Progress Across the Board, Expecting New Deals, Funded Through 1H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Poster Presentations at RDD Meeting Highlight TFF Advantages
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Highly Encouraging Presentations at RDD Meeting & New Online Publication
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Inhaled Niclosamide Dry Powder Proves Safe and Well Tolerated in Phase 1
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Clear Niclosamide, TFF VORI, & TFF TAC Progress, Expecting New Deals
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Signs CRADA with USAMRIID & Geneva Foundation for Medical Countermeasures
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Inhalation Dry Powder Development & Manufacturing Deal with Catalent
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J